INCOG BioPharma News and Resources

INCOG BioPharma Services, a contract development and manufacturing organisation (CDMO) specialising in sterile injectable biopharmaceuticals, is set to expand its manufacturing capabilities. The company will construct a second 100,000-square-foot building on its campus, starting in August. This expansion aims to

INCOG BioPharma Services, a biopharmaceutical contract manufacturing organisation, announced that its sterile injectable manufacturing facility has received approval from the U.S. Food and Drug Administration (FDA) to produce a commercially approved drug product. The FDA approval comes after a rigorous

INCOG BioPharma Services, a Contract Development and Manufacturing Organisation (CDMO), has announced a significant expansion in its production capacity. The company has added an impressive 100 million units to its syringe and cartridge capacity. The upcoming summer will see the